Fourth Quarter Concludes Successful Transformational Year, With Company Sharpening Focus and Laying a Foundation for Sustainable, Profitable Growth Recently Completed Sales of SinfonÃaRx and DoseMe Shares Full Year 2023 Revenue Guidance and Adjusted EBITDA Guidance MOORESTOWN, N.J., March…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.